The Claim
In adults aged 45 or older with cardiovascular disease and a BMI of 27 or higher but without diabetes, treatment with semaglutide over 34 months is associated with an absolute 1.5% reduction in the risk of major cardiovascular events, resulting in a number needed to treat of 67 to prevent one event, which represents a more realistic assessment of clinical benefit compared to the reported 20% relative risk reduction.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you're 45 or older, have heart disease, and are overweight but don’t have diabetes, taking semaglutide for about 3 years might lower your chance of having a serious heart problem by a small amount — about 1.5%. That means 67 people need to take it for one person to avoid a heart event, which gives a clearer picture than the often-shared 20% drop in risk.
See the scientific wording
In adults aged 45 or older with cardiovascular disease and a BMI ≥27 but without diabetes, semaglutide is associated with a 1.5% absolute reduction in the risk of major cardiovascular events over 34 months, meaning 67 people need to be treated to prevent one event, which provides a more realistic assessment of benefit than the 20% relative risk reduction often highlighted.
What the research says
1 studyStudy: Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
The study looked at semaglutide in people like those in the claim and found it prevented one heart problem for every 67 people treated over nearly 3 years, which matches the 1.5% benefit described.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.